CLAIMS

1. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing endometriosis-associated pain in a female human patient having endometriosis, wherein the compound is to be administered to the patient in an amount of about 200 mg per day.

2. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating endometriosis in a female human patient, wherein the compound is to be administered to the patient in an amount of about 200 mg per day.

3. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the concentration of β17-estradiol, follicle-stimulating hormone, and/or luteinizing hormone in a female human patient having endometriosis, wherein the compound is to be administered to the patient in an amount of about 200 mg per day.

4. The use of any one of claims 1-3, wherein the compound is to be administered to the patient in the form of a pharmaceutically acceptable salt thereof.

5. The use of any one of claims 1-3, wherein the compound is to be administered to the patient in the form of a choline salt thereof.

6. The use of any one of claims 1-3, wherein the compound is to be administered to the patient orally.

7. The use of any one of claims 1-3, wherein the compound is to be administered to the patient once daily.

8. The use of any one of claims 1-3, wherein the patient is to be further administered add-back therapy.

9. The use of claim 8, wherein the add-back therapy is to be administered to the patient once daily.

10. The use of claim 8, wherein the add-back therapy comprises an estrogen.

11. The use of claim 10, wherein the estrogen is β17-estradiol.

12. The use of claim 11, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day.

13. The use of claim 11, wherein the β17-estradiol is to be administered to the patient in an amount of about 0.5 mg per day.

14. The use of any one of claim 11-13, wherein the β17-estradiol is to be administered to the patient orally.

15. The use of claim 8, wherein the add-back therapy comprises a progestin.

16. The use of claim 15, wherein the progestin is norethindrone acetate.

17. The use of claim 16, wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

18. The use of claim 16, wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.1 mg per day.

19. The use of any one of claim 16-18, wherein the norethindrone acetate is to be administered to the patient orally.

20. The use of claim 8, wherein the add-back therapy comprises β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

21. The use of claim 8, wherein the add-back therapy comprises β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 0.5 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.1 mg per day.

22. A kit comprising a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein the compound is present in the kit in a unit dosage form comprising about 200 mg of the compound, and wherein the kit further comprises a package insert that instructs a user of the kit to administer the compound to a female human patient having endometriosis in an amount of about 200 mg per day.

23. The kit of claim 22, wherein the compound is present in the kit in the form of a pharmaceutically acceptable salt thereof.

24. The kit of claim 23, wherein the pharmaceutically acceptable salt is a choline salt.